(RTTNews) - Shattuck Labs, Inc. (STTK) Friday announced additional positive interim data from the Phase 1B study of SL-172154 in combination with Azacitidine (AZA) in frontline higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML) patients.
Objective response rate (ORR), percentage of people who have a partial response or complete response to the treatment, was 67 percent in HR-MDS patients, primarily with TP53 mutations, who were treated with SL-172154 plus AZA. 42 percent patients achieved a complete remission (CR) with 3.6 months as the median time to CR.
ORR was 43 percent in frontline TP53m AML patients, and 29 percent of patients achieved a CR.
Further, SL-172154 demonstrated a manageable interim safety profile in combination with AZA
"Enrollment is now underway for our randomized, controlled expansion cohort in frontline HR-MDS patients, and we expect to engage in regulatory discussions later this year regarding the registrational strategy for SL-172154," said Lini Pandite, Chief Medical Officer of Shattuck.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
